Document is current
Any future updates will be listed below
-
Authors
Tallon, Carolyn
Bell, Benjamin J.
Malvankar, Medhinee M.
Deme, Pragney
Nogueras-Ortiz, Carlos
Eren, Erden
Thomas, Ajit G.
Hollinger, Kristen R.
Pal, Arindom
Mustapic, Maja
Huang, Meixiang
Coleman, Kaleem
Joe, Tawnjerae R.
Rais, Rana
Haughey, Norman J.
Kapogiannis, Dimitrios http://orcid.org/0000-0003-2181-3118
Slusher, Barbara S. http://orcid.org/0000-0001-9814-4157
-
Funding
Funding for this research was provided by:
National Institute on Aging (R01 AG059799)
National Institute of Mental Health (P30 MH075673)
Alzheimer's Association (T-PEP-18-579974C)
Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease
National Institute of General Medical Sciences (R25GM109441)
- License Information
-
More Information
Article History
Received: 10 July 2023
Accepted: 23 October 2023
First Online: 4 December 2023
Declarations
:
: All animal care and experimental procedures complied with the National Institutes of Health guidelines on animal care and were reviewed for ethical use of animals and approved by the Johns Hopkins University Animal Care and Use Committee (protocol #MO20M71; approved on 18 March 2020).
: Not applicable.
: CT, AGT, RR, NJH and BSS are listed as inventors in patent applications filed by Johns Hopkins Technology Ventures covering novel compositions and utilities of nSMase2 inhibitors, including PDDC. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. Other authors declare that no conflict of interest exist.
